



Report #:

COA2607222-006

Page 1 of 2

Title:

Certificate of Analysis (CoA)



Date: 8/7/2026
Date Tested: 8/7/2026
Customer: Hamner Research
Testing material: Semaglutide
Lot Number: 01-2026
Content/Potency: 30 mg
Storage: R.T.
Visual Description: Small clear vial: white sample, holographic label, silver crimp, red plastic cap.
Labeled as: GLPS
Manufacturer: N/A
Testing Purpose: FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.



Test	Method	Specification	Result
General Appearance	USP <630>	white powder	white powder
Mass	USP <41>	As recorded	119.9 mg
FTIR Identification and Composition Analysis	USP <197A>	Sample spectrum should confirm the content of peptide via characteristic bands	FTIR sample spectrum confirms the presence of Semaglutide with addition of excipient(s)/fillers.
HPLC Purity of Peptide Assay	USP <621>	Specifications: $\geq 98\%$	99.9 %
HPLC Potency Assay	USP <621>	Specifications: 90 – 110% of 30 mg	34.4 mg (114.7 %)
Peptide-to-Excipients Ratio	USP <1151>	Recommended ratios of (1:2) to (1:10) for (peptide: excipients)	34.4 : 85.5 mg (1:2.5)

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

Andrea Castro, BS
Scientist-II
BTLabs

Escarlet Cabrieles, BS
Scientist-II
BTLabs

5601 Corporate Way | Suite 206 | West Palm Beach, FL 33407

Phone: (561) 625-0133


E-mail: info@btlabtesting.com | Website: <https://btlabtesting.com>

Title:

Certificate of Analysis (CoA)



FTIR ID and Composition Analysis: Semaglutide Lot 01-2026



HPLC Purity and Potency Assay @ 280 nm: Semaglutide Lot 01-2026



Semaglutide Lot 01-2026 @ 280 nm

Peak #:	Retention Time (min)	Area (mAU*s)
1	9.426	2437.1